Est with Bonferroni-corrected 2-tailed Student’s t tests as post-hoc tests) and presented as imply SEM. In circumstances in which data have been normalized to manage, 1-sample Student’s t test was applied with an expected worth of 1 or one hundred to be able to decrease the likelihood of a kind I error. To examine the statistical interaction among receptor expression and ligand treatment, 2-way ANOVA was performed with distinct interest inside the interaction term. The isolated impact of every person variable (represented by an ANOVA P value) was also noted in the figures and known as major impact receptor or primary impact FGF2. For all experiments, significance was set at P 0.05. Linear regression was performed on chosen microarray data, with all the slope and P value for the line of ideal match reported at the same time because the r2 value for the connection. All statistical analyses were carried out with GraphPad Prism version 6.00 (GraphPad Software). Study approval. All patient samples were deidentified, along with the project was exempted by the Duke University Wellness Technique Institutional Assessment Board (protocol ID 00034541). All animal procedures have been authorized by the Duke University Institutional Animal Care and Use Committee (protocol A278-11-11).Acknowledgments We thank Michael Hogarty, the Children’s Oncology Group Neuroblastoma Biology Subcommittee, Wendy London, and Evan Plunkett for delivering patient tissue and serum samples. We thank Linda Valentijn, Paul Yu, Harriett Stadt, Mary Hutson, Margaret Kirby, and Lisa Crose for giving reagents.Candesartan We thank Lindsey Morgan and Terri Lucas for coordinating our animal facility use.Chloroprocaine hydrochloride We thank Julie Fuller for tissue processing.PMID:23399686 We’re grateful to Tam How, Catherine Gatza, Alison Meyer, Alisha Holtzhausen, Catherine Lavau, Rebekah Moehring, Jennifer Elderbroom, Rachel Hesler, and Jasmine Nee for technical assistance and Cheryl Alles for superior clerical help. We are grateful to Daniel Wechsler, Dona Chikaraishi, Christopher Kontos, and Julio Ramirez for invaluable mentoring throughout this project. This operate was supported in portion by NIH grants F30 CA168043-01 (to E.H. Knelson), R01-CA136786 (to G.C. Blobe), and R01-CA135006 (to G.C. Blobe). Received for publication March 1, 2013, and accepted in revised form August 8, 2013. Address correspondence to: Gerard C. Blobe, Duke University Health-related Center, Box 91004, Durham, North Carolina 27708, USA. Telephone: 919.668.1359; Fax: 919.681.6906; E-mail: [email protected] 123 Number 11 Novemberhttp://www.jci.orgresearch article1. National Cancer Institute. Surveillance, Epidemiology and End Outcomes (SEER) Database. NIH Website. http://seer.cancer.gov/. Accessed August 30, 2013. two. Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD. Neuroblastoma: modern management. Arch Dis Youngster Educ Pract Ed. 2009;94(6):17785. 3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106120. four. De Bernardi B, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008; 26(10):1710716. 5. Retrosi G, et al. Morbidity following ganglioneuroma excision: is surgery necessary Eur J Pediatr Surg. 2011;21(1):337. 6. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010;29(11):1566579. 7. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202211. eight. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; three(3):20316. 9. S.
